Is Atrium Therapeutics, Inc. Common Stock (RNA) overvalued? · rev $10.9M
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
This page asks whether Atrium Therapeutics, Inc. Common Stock (RNA) looks expensive on cached numbers — not a short thesis.
Latest reported RNA revenue for 2024-12-31 was $10.9M. Net income was -$322.3M. Revenue was up 14.0% from 2023-12-31 to 2024-12-31. RNA currently screens at market cap $217.5M.
RNA currently screens at market cap $217.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RNA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RNA stock page for the full model, not this heading.
Not investment advice.